Love, a Miami, FL-based pharmaceutical group leveraging a community driven DAO, raised USD7.5M in Seed funding.
The round was led by Human Capital and MaC Venture Capital.
The company intends to use the funds to accelerate growth and expand operations.
Led by Ryan Breslow (former Bolt CEO), Love is a pharmaceutical group that listens and develops new treatments and healing technologies based on community feedback. To this end, the company is building a fast growing online patient communities as a network and is launching a DAO and accompanying token to fund and vote on trials to develop tomorrow’s best healing solutions. Members of the community can submit trial proposals, and share in the upside when treatments are launched. Initial focus areas include treating long COVID, Chronic Fatigue Syndrome, Fibromyalgia, and substance use disorders.
As part of the news, the company is announcing its Chief Medical Officer, Dr. Kevin Horgan, who previously held executive roles at healthcare giants AstraZeneca, GE Healthcare, and J&J, where he saw the need firsthand for a company like Love.
Stacy McIntosh is also joining as its Chief Regulatory Officer. She’s a 25-year industry veteran who most recently led the efforts for FDA approval of the Ebola therapeutic, Ebanga™ as well as initiation of the first in human study of the oral COVID-19 therapeutic, molnupiravir.
Since its founding, the team now has 15 employees including an executive bench of former leadership from companies like Bolt, Sweetgreen, and Headspace.
The Love DAO will be launched by December.
FinSMEs
17/08/2022